HiRO Acquires DeltaMed Solutions, Strengthening Global Clinical Research Capabilities

Harvest Integrated Research Organization (HiRO), a leading global Contract Research Organization (CRO), has recently expanded its reach by acquiring DeltaMed Solutions, a prominent US-based CRO. This acquisition marks HiRO's third strategic move since its establishment in 2020, solidifying its position as a comprehensive provider of clinical research solutions on a global scale.

With operations in multiple countries, including the US, Ireland, China, and Japan, HiRO is dedicated to offering efficient and customized trial solutions to pharmaceutical and biotech companies worldwide. The addition of DeltaMed Solutions, renowned for its expertise in data management, biostatistics, and regulatory affairs, further enhances HiRO's capabilities in conducting clinical trials across diverse therapeutic areas.

Dr. Karen Chu, CEO of HiRO, expressed confidence in the acquisition, emphasizing the synergies between the growth strategies of both organizations. Dr. Sam Liang, President of DeltaMed Solutions, highlighted the opportunity to contribute to HiRO's success and provide enhanced services to clients globally.

Together, HiRO and DeltaMed Solutions aim to deliver tailored clinical trial solutions that address specific market challenges and drive advancements in healthcare and pharmaceutical innovation. While HiRO offers a wide range of services from pre-clinical planning to project management, DeltaMed Solutions specializes in strategic partnerships and accelerating drug development.

The acquisition of DeltaMed Solutions by HiRO represents a significant step towards strengthening the capabilities of both organizations in the field of clinical research. This strategic partnership is poised to bring about innovative solutions that cater to the evolving needs of the healthcare and pharmaceutical industries, ultimately benefiting patients and advancing medical science.